Therefore, treatment of persons with advanced CRC still relies on oxaliplatin- and irinotecan-based chemotherapies in combination with monoclonal antibodies directed against vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and colorectal carcinoma.